GP – Page 17 – Myeloma Academy

Complications of myeloma and its treatments

Gastric submucosal haematoma caused by an amyloidoma in the setting of multiple myeloma. Pak SC et al. Arab J Gastroenterol. 2017 Dec 14. pii: S1687-1979(17)30116-8. doi: 10.1016/j.ajg.2017.12.002. [Epub ahead of print]. A case of Multiple Myeloma presenting with diffuse osteosclerosis and multiple bone infarcts. Vignon M et al. Joint Bone Spine. 2017 Dec 9. pii: S1297-319X(17)30203-8. doi: 10.1016/j.jbspin.2017.11.013. [Epub ahead of print]. Systolic dysfunction associated…

December 19, 2017Journal, Library, Management of complications & side effectsBy sarahfleming

NICE recommends ixazomib combination for relapsed and refractory myeloma patients

The National Institute of Health and Care Excellence (NICE) has recommended the use of ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for relapsed and refractory myeloma patients. This treatment will be made available through the Cancer Drugs Fund (CDF) to patients in England and Wales who have received 2 or 3 prior treatments. This…

December 19, 2017NewsBy sarahfleming

Supportive treatments

New agents in the Treatment of Myeloma Bone Disease.
Ring ES et al. Calcif Tissue Int. 2017 Nov 2. doi: 10.1007/s00223-017-0351-7. [Epub ahead of print].

Ciprofloxacin versus Levofloxacin for prophylaxis during Hematopoietic Stem Cell Transplantation.
Copeland V et al. Clin Transplant. 2017 Oct 28. doi: 10.1111/ctr.13145. [Epub ahead of print].

November 27, 2017Journal, Library, Myeloma Prognosis & OutcomesBy sarahfleming

General

Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma. Postmus D et al. Oncologist. 2017 Oct 27. pii: theoncologist.2017-0257. doi: 10.1634/theoncologist.2017-0257. [Epub ahead of print]. Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution. Jimenez-Zepeda VH et al. Leuk Lymphoma. 2017 Nov 21:1-7. doi:…

November 27, 2017Journal, LibraryBy sarahfleming

Current treatments

Final analysis of survival outcomes in the randomized phase 3 FIRST trial. Facon T et al. Blood. 2017 Nov 17. pii: blood-2017-07-795047. doi: 10.1182/blood-2017-07-795047. [Epub ahead of print]. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. Sivaraj D et al. Bone Marrow Transplant. 2017 Oct 30. doi: 10.1038/bmt.2017.208. [Epub ahead of print]. An overview of the…

November 27, 2017Journal, LibraryBy sarahfleming

Complications of myeloma and its treatments

Nonmyelomatous Ascites Resulting from the Increased Secretion of Vascular Endothelial Growth Factor in Multiple Myeloma. Maki H et al. Intern Med. 2017 Nov 20. doi: 10.2169/internalmedicine.8886-17. [Epub ahead of print]. Severe Hypoglycemia Caused by Lenalidomide. Przybylski DJ et al. Pharmacotherapy. 2017 Nov 20. doi: 10.1002/phar.2061. [Epub ahead of print]. Cardiovascular complications of multiple myeloma in the elderly. Mathur P et al. Expert Rev Cardiovasc Ther. 2017 Nov…

November 27, 2017Journal, Library, Management of complications & side effectsBy sarahfleming

IMWG Consensus of second primary malignancies in myeloma

This paper, written by a panel of experts from the International Myeloma Working Group (IMWG), reviews the available data on second primary malignancies in myeloma, and provides recommendations for treatment and management.

November 2, 2017Clinical guidelines & position statements, Complications, IMWG, LibraryBy sarahfleming

IMWG Consensus criteria for response and minimal residual disease in myeloma

This paper, produced by an expert panel of the International Myeloma Working Group (IMWG) reviews the assessment of disease response and endpoints for clinical trials, and provides updated response categories of minimal residual disease negativity.

Read abstract

November 2, 2017Clinical guidelines & position statements, Imaging & Analysis, IMWG, LibraryBy sarahfleming

IMWG Consensus statement on the treatment of myeloma patients with high-risk cytogenetics

This paper, produced by the International Myeloma Working Group (IMWG), provides an updated definition of high-risk myeloma based on cytogenetics and provides recommendations for the optimum treatment for this group of myeloma patients.

November 2, 2017Clinical guidelines & position statements, IMWG, Library, Management & TreatmentBy sarahfleming

IMWG Recommendations for the management of relapsed myeloma

This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the management of patients with relapsed myeloma.

Read abstract

November 2, 2017Clinical guidelines & position statements, IMWG, Library, Management & TreatmentBy sarahfleming

Archives: